Karen Basbaum
Corporate Officer/Principal presso POSEIDA THERAPEUTICS, INC.
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Mark Gergen | M | 61 | 6 anni | |
| Kristin Yarema | M | 53 | 1 anni | |
| Harry Leonhardt | M | 67 | 4 anni | |
| Johanna Mylet | F | 37 | 9 anni | |
| Marcea Lloyd | F | 75 | 5 anni | |
| Cynthia Collins | F | 65 | 3 anni | |
| John Schmid | M | 61 | 6 anni | |
| Charles Baum | M | 65 | 2 anni | |
| Kristin Martin | F | 49 | 5 anni | |
| Luke Corning | M | 41 | 4 anni | |
| Devon J. Shedlock | M | - | - | |
| Sarah Thailing | F | - | 4 anni | |
| Loren Wagner | M | - | 3 anni | |
| Rafael Amado | M | 60 | 1 anni | |
| Nina Kjellson | F | 49 |
Dauntless Pharmaceuticals, Inc.
 Dauntless Pharmaceuticals, Inc. Drugstore ChainsRetail Trade Dauntless Pharmaceuticals, Inc. develops specialty therapeutics via a one-asset, one-company model that is structured to facilitate operational efficiencies. The company was founded by Joel F. Martin and Michael F. Powell in May 2015 and is headquartered in San Diego, CA. | 7 anni |
| Lisa Portale | F | - | 5 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Eric Ostertag | M | 51 | 9 anni | |
| Martin R. Brown | M | - |
Elcelyx Therapeutics, Inc.
 Elcelyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elcelyx Therapeutics, Inc. develops novel therapeutics based on gut sensory modulation. Its product NewMet is being developed for use by type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. The firm also provides dietary supplements for weight management. The company was founded by Alain D. Baron in 2010 and is headquartered in San Diego, CA. | - |
| Danielle Campbell | F | - | 5 anni | |
| David Hirsch | M | 53 | 4 anni | |
| Catherine Mackey | M | 68 | 2 anni | |
| Sandy Mahatme | M | 59 |
Elcelyx Therapeutics, Inc.
Elcelyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elcelyx Therapeutics, Inc. develops novel therapeutics based on gut sensory modulation. Its product NewMet is being developed for use by type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. The firm also provides dietary supplements for weight management. The company was founded by Alain D. Baron in 2010 and is headquartered in San Diego, CA. | - |
| Mark Wiggins | M | 68 |
Elcelyx Therapeutics, Inc.
Elcelyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elcelyx Therapeutics, Inc. develops novel therapeutics based on gut sensory modulation. Its product NewMet is being developed for use by type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. The firm also provides dietary supplements for weight management. The company was founded by Alain D. Baron in 2010 and is headquartered in San Diego, CA. | 3 anni |
| Patrick Johnson | M | - | 2 anni | |
| Jeff Knight | M | 52 | 3 anni | |
| Matteo Levisetti | M | 55 |
Dauntless Pharmaceuticals, Inc.
Dauntless Pharmaceuticals, Inc. Drugstore ChainsRetail Trade Dauntless Pharmaceuticals, Inc. develops specialty therapeutics via a one-asset, one-company model that is structured to facilitate operational efficiencies. The company was founded by Joel F. Martin and Michael F. Powell in May 2015 and is headquartered in San Diego, CA. | 1 anni |
| Liang Tsui | M | - |
Elcelyx Therapeutics, Inc.
Elcelyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elcelyx Therapeutics, Inc. develops novel therapeutics based on gut sensory modulation. Its product NewMet is being developed for use by type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. The firm also provides dietary supplements for weight management. The company was founded by Alain D. Baron in 2010 and is headquartered in San Diego, CA. | - |
| Kerry Ingalls | M | - | 3 anni | |
| Thomas Bicsak | M | - |
Elcelyx Therapeutics, Inc.
Elcelyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elcelyx Therapeutics, Inc. develops novel therapeutics based on gut sensory modulation. Its product NewMet is being developed for use by type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. The firm also provides dietary supplements for weight management. The company was founded by Alain D. Baron in 2010 and is headquartered in San Diego, CA. | - |
| Mark S. Fineman | M | - |
Elcelyx Therapeutics, Inc.
Elcelyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elcelyx Therapeutics, Inc. develops novel therapeutics based on gut sensory modulation. Its product NewMet is being developed for use by type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. The firm also provides dietary supplements for weight management. The company was founded by Alain D. Baron in 2010 and is headquartered in San Diego, CA. | - |
| Richard Barry | M | 65 |
Elcelyx Therapeutics, Inc.
Elcelyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elcelyx Therapeutics, Inc. develops novel therapeutics based on gut sensory modulation. Its product NewMet is being developed for use by type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. The firm also provides dietary supplements for weight management. The company was founded by Alain D. Baron in 2010 and is headquartered in San Diego, CA. | 6 anni |
| Marcy Graham | F | 57 | - | |
| Matthew A. Spear | M | 57 | 6 anni | |
| Sean Murphy | M | 71 | 3 anni | |
| Brent Warner | M | 40 | 2 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 35 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Karen Basbaum
- Contatti personali
